A King's College Professor Cleared Statins of Muscle Pain. The Study He Cited Never Cleared It.
- 8 hours ago
- 13 min read
A response to Professor Tim Spector's Telegraph article
A physician's response to a popular statin story
Author: Qaisar J. Qayyum, MD
Clinical Assistant Professor, Internal Medicine and Geriatric Medicine, USA.
Chief Editor, Noor Journal of Complementary and Contemporary Medicine
Popular science writing in the Telegraph wasn't written for a peer-review audience, and it doesn't need to be. This piece asks something different of you as a reader: every claim examined here, the study cited, the numbers quoted, the mechanism named, can be checked against its original source, and none of it requires taking anyone's word for it, including mine. What follows is that check, applied evenly, to a piece read by millions.
I have a family history of coronary artery disease, and a personal one too. I still choose not to take statins. Every time I tried, my myalgias worsened, and some of that lingered at a moderate to severe level long after I stopped. Statins also carry a real risk of worsening insulin resistance, a serious concern for someone already managing diabetes.¹⁶
And the best-case return on that risk, even under ideal trial conditions, is small: out of 100 people followed for a year, about 1.36 would have a cardiovascular event without the drug, and 0.77, less than 1%, would have one if they take the drug.⁸ That's the real size of the benefit, half a percentage point a year, not the "1 in 30" figure Spector's article cites.¹ That's the actual trade I was weighing.
When a Title Does the Talking
The setting and presentation of his article caught our attention. I'm a physician myself, and being roughly his age, I've seen this pattern enough times over the years to recognize it immediately. None of what follows really surprised me. It's deceptive, and here's how.
There's one trick worth naming first, because it shows up in every point below. A title works on a reader before a single fact does. Many readers already know Spector holds the title "Professor," from his TV appearances or the ZOE nutrition app he co-founded, before they even open this article. Then, inside the piece itself, he adds a second title: "NHS rheumatologist." That title is from more than thirty years ago. He hasn't practiced under it since 1992, when he moved into genetic epidemiology full time. Used here, decades later, it sounds like a clinician still seeing patients. Even if he were still active as a rheumatologist, that specialty was never expected to manage high cholesterol or statin therapy in the first place. It was never their territory, even back when he was active.
By the time the real claim shows up, muscle pain, the nocebo effect, the "44 percent," most readers have already decided to believe it. Not because of the evidence. Because of who's talking.
It's interesting how casually he leans on this, knowing full well it has nothing to do with the actual clinical question, while counting on readers walking away thinking they've heard from an experienced, practicing clinician. That's the trick worth spotting, not just here, but anywhere. Set the title aside first. Then look at what's actually being claimed.
I did an HIV fellowship in 1994, and an infectious disease fellowship in 1998. I could flash my badge as an HIV expert and an infectious disease expert too. I won't. I haven't practiced either field in decades, and calling myself an expert now would mislead you. What I actually bring is decades of internal and geriatric medicine experience in UK and USA, and twenty years of my personal experience with statins. That's the disclaimer his sentence is missing.
One: two symptoms, easily confused, rarely explained
Professor Spector never uses the proper term myalgia anywhere in his article. He writes "muscle pains" and "muscle cramps" instead, using these terms to describe the same thing. But myalgia, not cramps, is what statins are generally known for and are the symptom patients are warned about. One major medical group that studies this even lists muscle cramps under myalgia, but only cramps tied to exercise. Nocturnal cramping, the kind that wakes someone up at night, exactly what Spector describes, is specifically carved out of that definition.²¹
This isn't a small mix-up. It's the same kind of mistake as confusing a sprained ankle with arthritis in that ankle because both are ankle pain, or chest wall pain with chest pain from the heart, because both come from the chest. Same general area, completely different condition.
He's a trained physician. A doctor with that training knows, or should know, the difference. So the real question is simple: why blur it?
Two: when the obvious explanation gets passed over
In his own words: he already had occasional cramps before starting the statin. Two weeks in, they got worse. He stopped the drug. The cramps kept happening anyway.
His own timeline answers the question by itself: the drug wasn't the cause. He didn't need any warning to explain what happened to him, he already had these cramps long before he ever touched a statin. There was nothing here to be alarmed about, just an old, pre-existing symptom, temporarily worse, then back to normal.
That old symptom settled down on its own, and improved further once he started taking vitamin K2, the way ordinary cramps respond to a real, tested remedy.¹¹
Instead of accepting that simple explanation, he reaches for something else entirely.
Three: misquoting a study to dismiss a symptom it never checked.
Here's his exact claim: "62 side effects, including muscle pains, were reported by people taking the dummy pills," just as often as by people on the actual drug.¹ That's the claim this section checks.
He cites a February 2026 Lancet paper as proof. That study tested 66 side effects. Only 4 were real. Got news for you: muscle pain wasn't one of the 66. The study's own chart proves it. Black circles mean tested and found real. Grey circles mean tested and found nothing. White circles mean excluded from testing entirely.² Muscle pain is marked with a white circle.
Why did the study exclude it? Because the same team had already studied muscle pain on its own, back in 2022, and found something real: a small but genuine rise in muscle pain and weakness in the first year on the drug, roughly one extra case per hundred patients, with no added risk after that.³
Spector isn't the only one who ran with this without digging into what it actually excluded. A press release covering the same study, from the University of Oxford, went out under the headline "Massive study finds most statin side effects aren't caused by the drugs," published February 15, 2026.⁴ Read carefully, that headline is just as sweeping, and just as wrong about muscle pain specifically, as his own summary of it.
This is disappointing to see from a professor at King's College London and a career researcher. A white circle instead of a grey one, with the study's own caption spelling out the difference, is about as clear a signal as a paper can give that something wasn't tested, not tested and cleared. Turning a clear non-finding into a stated finding, and telling millions of readers their muscle pain has been checked and cleared, isn't the kind of mistake a career built on reading data should make.
Four: the nocebo effect misrepresented
Mixing up two symptoms is not a mistake you'd expect from a clinician. And it's disappointing to watch how a researcher stretched a real scientific term until it fits whatever presentation he happens to have, instead of checking if it actually applies.
He writes: "It's known as the 'nocebo effect'... I was so convinced that I would suffer from muscle cramps, that it happened."¹ That's the claim this section checks.
Nocebo means a negative expectation can produce a real symptom, even though the drug itself isn't the cause. Myalgia, not cramps, is what statins are generally known for and what that kind of expectation would actually be built around.
He already had those cramps before he ever touched the drug. That's an old symptom, flaring and fading the way it always had. Nothing needed to plant an expectation in his mind, because the symptom was already there, waiting to flare up again on its own. It's like someone with an old, occasional knee ache starting a new supplement, then feeling that same ache on a damp, rainy day, the way it always has, and blaming the supplement instead of the weather. They got worse, then settled down on their own. That's not nocebo.
Suppose, for the sake of argument, we call it nocebo anyway. It still has nothing to do with the statin. He had these cramps before he ever started the drug, so whatever caused them the first time is still the most likely explanation for why they came back. And suppose we go further still, and grant that this really is what happened to him. Even then, one person's experience doesn't generalize. It doesn't tell us anything about what causes muscle symptoms in other patients on statins.
Five: "Rubbish"? A rubbish claim
Professor Spector writes: "Not only did the majority of the worries about statin side effects turn out to be rubbish, I saw first-hand how they can actually benefit your health."¹ A sweeping claim. No source attached. Just a statement expected to be believed because he holds a medical title. A few months of personal experience, dressed up as a life-changing verdict on a drug he's recommending people take for the rest of their lives.
Here's the problem with "rubbish." The very same 2026 study he cites elsewhere in his article, the one he treats as clearing statins of most side effects, states plainly, in its own words: statins cause a real, dose-related rise in new diabetes, especially in people whose blood sugar is already borderline.² That's not a small footnote. For a diabetic patient, it's a real, documented cost. And it comes from the same paper he's using to call patient concerns "rubbish."
Six: inventing a standard no major guideline recognizes.
He writes: "My inflammation levels, measured by a high-sensitivity C-reactive protein (hs-CRP) test, have fallen by 40 per cent since I started the drug."¹ He treats that as personal proof the statin is working. Maybe. But if it really worked that way, why haven't guidelines caught up to this?
The link between CRP and cardiovascular outcomes is real and well-studied.¹²,¹³ No major guideline, American or European, recommends routine CRP retesting to judge whether a statin is working. The concept has been floated as a hypothesis in cardiology literature, based on post-hoc trial data, but even guideline authors have called the evidence too thin to turn it into an actual recommendation.⁵
The most current joint guideline from the American College of Cardiology and American Heart Association calls for a lipid panel 4 to 12 weeks after starting or adjusting therapy, then every 6 to 12 months after that.⁵ CRP doesn't appear anywhere in that follow-up schedule.
Seven: the illusion in the numbers
He says statins prevent "one major cardiovascular event in every 30 people." He doesn't name a trial. The number most closely matches JUPITER, the landmark trial for rosuvastatin 20mg, the exact drug and dose he says he takes.⁸ It's likely where the figure comes from, though he never says so directly.
There are many kinds of numbers used in medicine, but the two that matter most here are relative and absolute. A relative number tells you how two groups compare to each other. An absolute number tells you what actually happens to you. Behind his "1 in 30" claim sits a 44 percent relative risk reduction, the actual figure from JUPITER. On its own, that number means nothing to you personally.
Now the absolute number, the one that actually matters. JUPITER found: 1.36% of people on placebo had an event in a single year. 0.77% of people on the drug did, that same year. That's the real difference, per year: about half a percent. That is the actual arithmetic behind the trial he's likely drawing from.
Let's look at the bigger picture, over a longer stretch of time. For people without existing heart disease, the typical benefit added up over five full years of taking the drug is closer to just 1-2%, sometimes less.¹⁷,¹⁸,¹⁹ Spread evenly across five years, that works out to somewhere around 0.2 to 0.4 percent per year, even smaller than the JUPITER figure above. For people at the lowest risk, one summary of the research found no statistically significant reduction in death at all, based on a meta-analysis of 22 trials and over 130,000 patients.²⁰
One must remember this difference. Relative number: sounds big, tells you nothing about your own odds. Absolute number: sounds small, tells you the truth. Every time a headline quotes a percentage, ask which one you're looking at.
Eight: the evidence that got left out
Professor Spector writes: "there are signs that, by lowering inflammation in our gut, statins are changing the composition of the microbes that live in our intestines."¹ No study named, no citation. The most likely research behind that claim is a study comparing statin users to non-users, and that study's own lead researcher said on the record: "this study design does not allow inferring causality."¹⁰
Meanwhile, actual lab studies looking for cause and effect point the other way. One found statins harm gut bacteria health through a specific biological pathway in murine model.¹⁴ Another found statins can cause "leaky gut" and disrupt blood sugar control.¹⁵ A third found statins can worsen insulin resistance through changes in gut bacteria.¹⁶ For someone with diabetes, that's the opposite of good news.
His dementia and antidepressant claims get an honest caveat in his own words: "while not concrete yet, are very promising."¹ The gut microbiome claim gets no such caution, even though it deserves the same one.
Nine: "Trust me, I'm a doctor."
By this point, he's already misapplied a study, redefined a scientific term to fit his own symptom, and called patient concerns "rubbish" with nothing to back it up. His closing line is where all of that gets cashed in. It doesn't sound like evidence, because it isn't.
His closing line: "It's all so encouraging that I've decided to stay on statins, I've been taking them since last February, with just a few months' break when I thought they were behind my muscle cramps, and monitor my progress as time goes on."¹
Strip away the impressive titles, and here's what that sentence really says: "I've been on this pill a few months, minus a break, and I feel good about it." One person's experience, presented as a success story for readers to follow. Not a study. Not even a group.
That's not a conclusion. That's a guess wearing a lab coat.
Ten: right study, wrong symptom
He never names a trial for his vitamin K2 claim. Here's his full quote: "While there's really no magic treatment for them, I've found that vitamin K2 helps... it is the best studied in a clinical trial for easing muscle pain."¹ Searching for the actual research behind that claim turns up one clear match: a study specifically about nighttime leg cramps in older adults, not muscle pain.¹¹
The trial tested cramps. His own words say muscle pain. That's not what it tested.
Two Truths Left Out
Two real, physical explanations for statin muscle pain exist, and neither one made it into his article.
The first is a mechanism, not just a statistic. In January 2026, Columbia scientists watched it happen at the molecular level: a statin physically forcing open a channel in muscle cells, causing damage over time.⁹ Not a survey response. An actual photograph of the process happening.
The second is a diagnosis. There's a rare disease where the body's immune system attacks its own muscle after a statin, confirmed by blood test, sometimes biopsy.⁶,⁷ Unlike ordinary muscle aches, it often doesn't go away when the drug stops.
Both are rare. Both are real. And both are exactly what "it's probably just in your head" misses.
None of this is an argument against the drug. It's an argument for reading the actual research yourself, before trusting a headline.
A Responsible Telegraph
We're not asking the Telegraph to retract this piece in its entirety. Much of it is personal experience and framing, not something a correction process exists for. But one specific claim in it is factually false in a way that's easy to check and hard to defend: the article states that a large 2026 study found muscle pain occurred no more often on statins than on placebo. The study's own chart says otherwise, muscle pain wasn't tested in that comparison at all, marked with a different symbol than every outcome the study actually assessed, with the paper's own caption explaining why. That's not a matter of interpretation. It's a factual misstatement of what a cited study found, the kind of error most reputable outlets correct once it's brought to their attention.
We'd encourage the Telegraph to issue a correction making this plain to the readers who saw the original claim: the study did not clear statin-associated muscle pain. It excluded it from testing entirely, because the same research group had already found a real, if small, effect in earlier work. Readers deserve to know that distinction as clearly as they were told the opposite.
Acknowledgment:
This article was written with AI assistance. All claims are supported by credible, peer-reviewed references, which were validated for accuracy and authenticity. The AI synthesized information were reviewed by author, ensuring scientific integrity throughout. In the event of any inadvertent errors, the responsibility lies with the AI/authors, and corrections will be made promptly upon identification.
Conflict of Interest Statement:
The author is the developer of a herbal formula and the owner of Dr. Q Formula/Insulinn LLC. However, this affiliation has not influenced the content, analysis, or conclusions of this article
Author’s Note on Scope and Intent:
This article does not advocate the replacement of evidence-based conventional care modalities. All complementary interventions are intended to supplement, not supplant, standard clinical practice, and are implemented within a physician-governed, ethically reviewed, and fully documented medical framework.
References
Spector T. Why I'm taking statins after avoiding them for nearly a decade. The Telegraph. July 7, 2026. https://www.telegraph.co.uk/health-fitness/diet/nutrition/tim-spector-statins-sceptic-now-convert/
Cholesterol Treatment Trialists' (CTT) Collaboration (Reith C, et al.). Assessment of adverse effects attributed to statin therapy in product labels. Lancet. 2026;407(10529):689-703. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)01578-8/fulltext
Reith C, Baigent C, Blackwell L, et al. Effect of statin therapy on muscle symptoms. Lancet. 2022;400(10355):832-845. https://pmc.ncbi.nlm.nih.gov/articles/PMC7613583/
University of Oxford. Massive study finds most statin side effects aren't caused by the drugs. ScienceDaily. Feb 15, 2026. https://www.sciencedaily.com/releases/2026/02/260212025550.htm
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. J Am Coll Cardiol. 2026. https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016
Anti-HMGCR-Antibody-Positive Statin-Induced Myositis. Antibodies (Basel). 2025;14(3):63. https://pmc.ncbi.nlm.nih.gov/articles/PMC12372103/
Anti-HMGCR myopathy secondary to statins diagnosed in the emergency department. ScienceDirect. 2025. https://www.sciencedirect.com/science/article/pii/S2949918625000397
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359(21):2195-2207. https://www.nejm.org/doi/full/10.1056/NEJMoa0807646
Columbia University Irving Medical Center. Scientists finally uncover why statins cause muscle pain. ScienceDaily. Jan 14, 2026. https://www.sciencedaily.com/releases/2026/01/260114084122.htm
Vieira-Silva S, Falony G, Belda E, et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis. Nature. 2020;581(7808):310-315. Quote from lead author available at: https://www.sciencedaily.com/releases/2020/05/200506133629.htm
Tan J, Zhu R, Li Y, et al. Vitamin K2 in Managing Nocturnal Leg Cramps: A Randomized Clinical Trial. JAMA Intern Med. 2024;184(12):1443-1447. https://pmc.ncbi.nlm.nih.gov/articles/PMC11581596/
Ridker PM, Cannon CP, Morrow D, et al. C-Reactive Protein Levels and Outcomes after Statin Therapy. N Engl J Med. 2005;352(1):20-28. https://www.nejm.org/doi/full/10.1056/NEJMoa042378
Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119-1131. https://www.nejm.org/doi/full/10.1056/NEJMoa1707914
Caparrós-Martín JA, Lareu RR, Ramsay JP, et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome. 2017;5:95. https://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-017-0312-4
The Intestinal Effect of Atorvastatin: Akkermansia muciniphila and Barrier Function. Front Microbiol. 2021. https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2021.797062/full
Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner. Cell Metabolism. https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00505-3
Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-1681. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61350-5/fulltext
Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC9812424/
Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226996/
Statins in Persons at Low Risk of Cardiovascular Disease. TheNNT. https://thennt.com/nnt/statins-persons-low-risk-cardiovascular-disease/
Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S58-S71. https://pubmed.ncbi.nlm.nih.gov/24793443/
Comments